The bidding battle for Oxford GlycoSciences is finally over, with Celltech the hands-down winner. But OGS’ proteomics business unit will likely not be part of the merged company.
Last Wednesday, Celltech, of Slough, UK, said it had acquired or received acceptance for just over 61 percent of OGS’ shares, making its all-cash offer of £101.4 million ($160 million) for the company unconditional. Celltech also appointed a new CEO that day — Göran Ando, who joins the company from Pharmacia (see p.2) and will now face the task of integrating the new acquisition.